Literature DB >> 11157898

Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus.

T Wichelhaus1, V Schäfer, V Brade, B Böddinghaus.   

Abstract

The in vitro antibacterial activities of the rifamycin derivatives rifampicin and KRM-1648 against 150 Staphylococcus aureus isolates were determined. The MICs of rifampicin and KRM-1648 for 90% of rifampicin-susceptible S. aureus isolates (n = 100) were 0.016 and 0.001 mg/L, respectively. In rifampicin-resistant S. aureus isolates (n = 50), different levels of resistance to rifamycins were associated with mutations at different sites in rpoB. Mutations at some sites were associated with high-level resistance to both rifamycins, while certain mutations were associated with the activity of KRM-1648 being < or = 100-fold better than that of rifampicin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11157898     DOI: 10.1093/jac/47.2.153

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

1.  rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin.

Authors:  Wafa Achour; Olfa Guenni; Marguerite Fines; Roland Leclercq; Assia Ben Hassen
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.

Authors:  David M Rothstein; Ronald S Farquhar; Klari Sirokman; Karen L Sondergaard; Charles Hazlett; Angelia A Doye; Judith K Gwathmey; Steve Mullin; John van Duzer; Christopher K Murphy
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 3.  Mechanisms of physiological regulation of RNA synthesis in bacteria: new discoveries breaking old schemes.

Authors:  Agnieszka Szalewska-Palasz; Grzegorz Wegrzyn; Alicja Wegrzyn
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

Review 4.  Whole-genome sequencing in outbreak analysis.

Authors:  Carol A Gilchrist; Stephen D Turner; Margaret F Riley; William A Petri; Erik L Hewlett
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

5.  Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil.

Authors:  Robert J Suchland; Agnès Bourillon; Erick Denamur; Walter E Stamm; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.

Authors:  Longzhu Cui; Taisuke Isii; Minoru Fukuda; Tomonori Ochiai; Hui-Min Neoh; Ilana Lopes Baratella da Cunha Camargo; Yukiko Watanabe; Mitsutaka Shoji; Tomomi Hishinuma; Keiichi Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2010-09-13       Impact factor: 5.191

7.  In Vitro Activity of Rifampin, Rifabutin, Rifapentine, and Rifaximin against Planktonic and Biofilm States of Staphylococci Isolated from Periprosthetic Joint Infection.

Authors:  Mariana Albano; Melissa J Karau; Kerryl E Greenwood-Quaintance; Douglas R Osmon; Caitlin P Oravec; Daniel J Berry; Matthew P Abdel; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

8.  Novel riboswitch ligand analogs as selective inhibitors of guanine-related metabolic pathways.

Authors:  Jérôme Mulhbacher; Eric Brouillette; Marianne Allard; Louis-Charles Fortier; François Malouin; Daniel A Lafontaine
Journal:  PLoS Pathog       Date:  2010-04-22       Impact factor: 6.823

9.  In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.

Authors:  Christopher K Murphy; Steve Mullin; Marcia S Osburne; John van Duzer; Jim Siedlecki; Xiang Yu; Kathy Kerstein; Michael Cynamon; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates.

Authors:  Silke Besier; Johannes Zander; Barbara C Kahl; Peter Kraiczy; Volker Brade; Thomas A Wichelhaus
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.